Utilizing the NanoString, Seattle, Washington, United States, nCounter PanCancer Immune Profiling Panel, they discovered that BM from EGFR-mutated adenocarcinoma exhibited increased activation of various immune-related pathways when compared to EGFR-wild-type adenocarcinoma. Here, EGFR is linked to adenocarcinoma.